Externally indexed torrent

If you are the original uploader, contact staff to have it moved to your account

Textbook in PDF format

Case studies of 20 successful FDA-approved drugs, from biological rationale to clinical efficacy studies and state-of-the-art applications.
Chemistry and Pharmacology of Drug Discovery illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021―some of which are first-in-class and revolutionary.
The four sections in this book cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety.
This book is contributed to by various veterans and well-known experts in medical chemistry, many of whom discovered the drugs they reviewed, leading to tremendous quality and depth of insight.
Some of the drugs covered in Chemistry and Pharmacology of Drug Discovery include:
Nirmatrelvir (Paxlovid with Ritonavir), a 3-chymotrypsin-like protease inhibitor for treating SARS-CoV-2 infection.
Doravirine (Pifeltro), a third-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Oteseconazole (Vivjoa), a CYP51 inhibitor for treating recurrent vulvovaginal candidiasis, and Rimegepant (Nurtec ODT), a CGRP antagonist for treating migraine
Ciprofol (Cipepofol), a γ-Aminobutyric acid receptor agonist for induction of anesthesia, and Ozanimod (Zeposia), an S1P receptor antagonist for treating multiple sclerosis.
Deucravacitinib (Sotyktu), a first-in-class deuterated TYK2 inhibitor for the treatment of plaque psoriasis.
Chemistry and Pharmacology of Drug Discovery serves as an excellent and highly authoritative learning resource for medicinal, organic, synthetic, and process chemists as well as research scientists in lead optimization and process development.
Nirmatrelvir (Paxlovid with Ritonavir): A 3-Chymotrypsin-like Protease Inhibitor for Treating SARS-CoV-2 Infection
Doravirine (Pifeltro): A Third-generation Nonnucleoside Reverse Transcriptase Inhibitor as a Treatment of HIV-1 Infection
Cabotegravir (Vocabria) An HIV Integrase Strand Transfer Inhibitor for Treating HIV Infection
Lenacapavir (Sunlenca): A Long-acting HIV-1 Capsid Protein Inhibitor for Treating HIV Infection
Fostemsavir (Rukobia) An HIV-1 gp120-Direceted Attachment Inhibitor for Treating AIDS
Oteseconazole (Vivjoa) A CYP51 Inhibitor for Treating Recurrent Vulvovaginal Candidiasis
Futibatinib (Lytgobi) A Selective Irreversible FGFR1‒4 Inhibitor
Pacritinib (Vonjo) A Dual JAK2/IRAK1 Inhibitor for Treating Myelofibrosis
Tucatinib (Tukysa) An Oral, Selective HER2 Inhibitor for the Treatment of HER2-positive Solid Tumors
Tazemetostat (Tazverik) An EZH2 Inhibitor for Treatment of Epithelioid Sarcoma and Follicular Lymphoma
Ozanimod (Zeposia): An S1P Receptor Modulator for Treating Multiple Sclerosis and Inflammatory Bowel Diseases
Ciprofol (Cipepofol): A γ-Aminobutyric Acid Receptor Agonist for Induction of Anesthesia
Rimegepant (Nurtec ODT): A CGRP Receptor Antagonist as a Treatment of Episodic Migraine
Daridorexant (Quviviq): An Antagonist of Orexin Receptors for Treating Insomnia
Deucravacitinib (Sotyktu): A First-in-Class Deuterated TYK2 Inhibitor for the Treatment of Plaque Psoriasis
Bremelanotide (Vyleesi): A Melanocortin Receptor Agonist for Treating Female Hypoactive Sexual Desire Disorder
Odevixibat (Bylvay): A Selective Inhibitor of the Ileal Bile Acid Transporter